(CTXR) Citius Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US17322U2078

CTXR: Immunotherapy, Antibiotic, Topical Formulation, Catheter Solution

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a biopharmaceutical company specializing in the development and commercialization of critical care and oncology products. The companys lead approved product, LYMPHIR, is an FDA-cleared immunotherapy designed for the treatment of cutaneous T-cell lymphoma (CTCL). Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution currently in Phase 3 trials for the salvage of infected central venous catheters in patients with catheter-related bloodstream infections (CRBSIs), and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids, which has completed Phase 2b trials. The company was established in 2007 and operates from its headquarters in Cranford, New Jersey. For more information, visit https://citiuspharma.com.

Ticker Symbol: CTXR
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 87,107
Last Price: 1.79
SMA 20: 2.05
SMA 50: 2.80
SMA 200: 10.39
ATR: 0.27

Market Cap: $14.09M USD
P/E: 0.00
P/E Forward: 9.13
P/B: 0.22
P/S: 0.00
RoE: -60.66

3-Month Forecast:
Based on the analysis of and , CTXR is expected to experience continued volatility within the $1.50-$2.50 range. The stock is currently trading below its SMA 20 and SMA 50, indicating bearish momentum. However, the forward P/E of 9.13 suggests potential undervaluation. The negative RoE and low market cap highlight significant risks, but the completion of late-stage trials for Mino-Lok and CITI-002 could act as catalysts for upside movement. ATR of 0.27 indicates moderate price fluctuations.

Additional Sources for CTXR Stock

CTXR Stock Overview

Market Cap in USD 14m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2017-07-06

CTXR Stock Ratings

Growth 5y -83.7%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -91.4
Analysts 4.33/5
Fair Price Momentum 1.17 USD
Fair Price DCF -

CTXR Dividends

No Dividends Paid

CTXR Growth Ratios

Growth Correlation 3m -74.4%
Growth Correlation 12m -92%
Growth Correlation 5y -60.7%
CAGR 5y -34.52%
CAGR/Max DD 5y -0.35
Sharpe Ratio 12m -2.61
Alpha -103.18
Beta 1.18
Volatility 81.49%
Current Volume 47.1k
Average Volume 20d 82.3k
What is the price of CTXR stocks?
As of March 15, 2025, the stock is trading at USD 1.50 with a total of 47,077 shares traded.
Over the past week, the price has changed by -16.20%, over one month by -44.24%, over three months by -41.86% and over the past year by -91.29%.
Is Citius Pharmaceuticals a good stock to buy?
No, based on ValueRay Analyses, Citius Pharmaceuticals (NASDAQ:CTXR) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -83.69 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTXR as of March 2025 is 1.17. This means that CTXR is currently overvalued and has a potential downside of -22%.
Is CTXR a buy, sell or hold?
Citius Pharmaceuticals has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy CTXR.
  • Strong Buy: 1
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CTXR stock price target?
According to ValueRays Forecast Model, CTXR Citius Pharmaceuticals will be worth about 1.3 in March 2026. The stock is currently trading at 1.50. This means that the stock has a potential downside of -13.33%.
Issuer Forecast Upside
Wallstreet Target Price 39 2500%
Analysts Target Price 4.7 211.3%
ValueRay Target Price 1.3 -13.3%